Abstract: BCR/ABL1-like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B-lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that of true BCR/ABL1-positive cases, and have a heterogeneous genetic background and a poor outcome. Next-generation sequencing studies have demonstrated that the majority of patients carry rearrangements of tyrosine kinases or cytokine receptors and mutations of janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus opening the way to the possible use of targeted therapeutic approaches. However, several issues remain unresolved at both the diagnostic and therapeutic level, such as the definition of a standardized method to identify BCR/ABL1-like ALL and the design of ad hoc clinical trials examining tyrosine kinase inhibitors or other tailored treatments. These aspects are discussed in this review. Cancer 2019;125:194-204.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most frequent cancer diagnosed in children. Although it decreases in adolescence and adulthood, a second peak can be recorded starting from the sixth decade of life onward. 1 The outcome of patients with ALL has improved in the last decades, particularly in children, for whom the intensification of treatment, patient stratification based on clinical risk factors, and minimal residual disease (MRD) monitoring have led to cure rates approaching 80% to 90%. 2 When applying the above mentioned principles to adolescents and young adults, the 5-year survival rates are reported to be approximately 50% to 60%. In adults and the elderly, the scenario still is disappointing because of the presence of poor-prognosis genetic subgroups and comorbidities, which hamper the possibility of the patient receiving high-dose chemotherapy and undergoing allogeneic transplantation procedures. 3 The introduction of genome-wide technologies has elucidated the molecular mechanisms underlying leukemic transformation in a percentage of patients with ALL and has allowed for the identification of previously unknown subgroups.
In 2005, using gene expression profiling, Haferlach et al 4 and our group 5 demonstrated that within adult patients with B-lineage ALL not harboring major molecular aberrations (BCR/ABL1, lysine methyltransferase 2 [KMT2A], and transcription factor 3 [TCF3]/pre-B-cell-leukemia transcription factor 1 [PBX1]), a percentage of cases clustered tightly with "true BCR/ABL1-positive cases"; however, at that time, these cases were only described and no further characterization was performed. In 2009, researchers from both the Dutch Childhood Oncology Group (DCOG) 6 and the St. Jude Children's Research Hospital 7 described in the pediatric setting a similar subset that was associated with a poor outcome: they termed this subset "Philadelphia-like" or BCR/ABL1-like ALL (herein defined as BCR/ABL1-like ALL).
This subset of patients accounts for approximately 20% of B-lineage ALL cases overall, and is detected exclusively in those individuals lacking BCR/ABL1, KMT2A rearrangements, and TCF3/PBX1. In pediatric cohorts, approximately 10% to 15% of patients with B-lineage ALL demonstrate a BCR/ABL1-like profile, although a higher prevalence (approximately 25%) has been described in adolescents and young adults, whereas the incidence in adults is reported to be 20% to 30%, [8] [9] [10] [11] [12] depending on the cohorts analyzed, the population considered, and the assay(s) used for their detection.
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This review will focus on these 3 topics.
Identification of BCR/ABL1-Like ALL
The authors who first described BCR/ABL1-like ALL used 2 different approaches for their identification. 6, 7, 13, 14 The DCOG group selected the most discriminative 110-probe set capable of predicting with high accuracy the major pediatric subtypes of ALL (T-cell ALL, translocation-Ets-leukemia virus [ETV6 ]-runt-related transcription factor 1 [RUNX1], ALL with high hyperdiploidy, and TCF3-or MLL-rearranged ALL); in addition, they used the probe sets distinctive of the BCR/ABL1-positive and MLL-rearranged cases identified by Ross et al. 15 Hierarchical clustering (HC) of the entire cohort using this gene list allowed for the identification of BCR/ABL1-like cases: this subset, accounting for approximately 19% of patients with ALL, was characterized by a higher incidence of relapse and an inferior disease-free survival compared with the patients with the other BCR/ABL1-negative B-lineage ALL.
At variance, Mullighan et al 7 compared the transcriptional profiles of patients with BCR/ABL1-positive and BCR/ABL1-negative ALL with a poor outcome and found a high degree of similarity between these subsets using gene set enrichment analysis. The same group confirmed the high degree of overlap between the cluster of high-risk patients and the BCR/ABL1-like subset, and contributed to the refinement of the characterization of this novel entity. 13, 14 Moreover, they subsequently refined the identification method and used a prediction analysis of microarray (PAM) classifier consisting of 257 gene probe sets trained on BCR/ ABL1-positive cases. 16 Both studies 6, 7 reported that patients with BCR/ABL1-like ALL were characterized by a higher incidence of IKAROS family zinc finger 1 (IKZF1), early B-cell factor-1 (EBF1), paired box gene 5 (PAX5), and V-set pre-B cell surrogate light chain 1 (VPREB1) deletions, janus kinase (JAK) mutations, and cytokine receptor-like factor 2 (CRLF2) rearrangements/overexpression when compared with the remaining B-lineage ALL samples.
However, when the signatures by Den Boer et al 6 and Mullighan et al 7 were compared, only 9 probe sets (among 110 probe sets and 257 probe sets, respectively) overlapped; similarly, by classifying the same set of patients with both methods, the majority of PAM BCR/ ABL1-like ALL cases (75%-79%) were defined as BCR/ ABL1-like ALL also by HC, whereas only 31% to 33% of cases identified as BCR/ABL1-like ALL by HC were identified also by PAM. 17 Both signatures recognized BCR/ABL1-like cases harboring kinase-activating fusions, IKZF1 and VPREB1 deletions, and iAMP21. It is interesting to note that the PAM BCR/ABL1-like group was enriched with CRLF2 aberrant cases, which is consistent with the association between CRLF2 rearrangements and Hispanic ethnicity that has been highly represented in the US cohort (Fig. 1) . 18 These discrepancies most likely reflect the different composition of the discovery cohorts (i.e., ethnicity and risk category) and the algorithm used (ie, HC vs PAM), and highlight the challenge of developing a standard method for the univocal recognition of BCR/ABL1-like ALL cases.
Screening Methods
Given the difficulties in implementing gene expression profiling and next-generation sequencing in the diagnostic routine, the more recent studies have adopted predictive algorithms based on quantification of the expression of selected predictor genes and/or the integration of multiple techniques (Fig. 2) . 9, 12, 16, [19] [20] [21] [22] [23] With regard to the first approach, the quantification of transcripts was performed either by low-density array (LDA) or quantitative real-time polymerase chain reaction (Q-RT-PCR), and the majority of them refer to the method developed by Harvey et al, 19 who developed a 15-gene LDA classifier. The latter method and its scoring system later were used by Roberts et al. 8 It is interesting to note that BCR/ABL1-like ALL cases harboring tyrosine kinase (TK) rearrangements display higher scores.
Along the same line, other predictors were developed. Roberts SEMA6A) and used their expression values together with CRLF2 transcript quantification to build a predictive tool based on Q-RT-PCR.
Thus, the genes selected to perform LDA or Q-RT-PCR partly overlap. In particular, the recurrent genes were found to be JCHAIN, SEMA6A, TP53INP1, IFITM1, and, partly, CRLF2. The predictions resulting from LDA may be integrated with an in-depth genetic characterization to demonstrate the underlying genetic features as suggested by Roberts et al. 16, 24 In both flow charts, LDA-positive cases were subdivided according to CRLF2 expression/rearrangements; next, CRLF2-positive cases were tested for the presence of JAK/STAT mutations, whereas CRLF2-negative samples were analyzed for the presence of TK rearrangements either by multiplex RT-PCR or RNA-sequencing approaches. The approaches based on LDA/Q-RT-PCR screening are advantageous because they allow us to limit the in-depth genetic studies to a minority of cases (10%-30%) classified as BCR/ABL1-like ALL by the predictor. Moreover, these approaches also recognize cases with an unknown genetic background as opposed to methods based on the combination of multiple techniques, as proposed by Fasan et al 22 and Jain et al. 23 As a further confirmation of the heterogeneity of these methods, it is worth mentioning that a provisional entity of "B-ALL with translocations involving tyrosine kinases or cytokine receptors (BCR/ABL1-like ALL)" has been added to the 2016 World Health Organization classification of myeloid neoplasms and acute leukemias, but to our knowledge the diagnostic criteria are not reported. 25 In this respect, one of the primary outcomes of the trial promoted by the New Mexico Cancer Care Alliance (ClinicalTrials.gov identifier NCT02580981) is indeed the evaluation of the robustness of the LDA card prediction for the identification of BCR/ABL1-like ALL.
Clinical Features of BCR/ABL1-Like ALL
Patients with BCR/ABL1-like ALL often are of male sex, are mainly young adults, and are characterized by hyperleukocytosis at the time of onset of the disease. As already mentioned, in addition to the peculiar transcriptional profile, the interest in this subset of patients also derives from the worse outcome noted among pediatric patients with BCR/ABL1-like ALL due to an inferior response to induction therapy, a higher incidence of relapse, and lower survival compared with the remaining B-cell ALL BCR/ABL1-negative cases. 6, 7 Furthermore, in a multivariate analysis, the BCR/ABL-like ALL subtype represented an independent risk factor. 6 Subsequently, Roberts et al 26 studied a broad cohort of pediatric patients with ALL who were enrolled in MRD-driven protocols and highlighted that pediatric patients with BCR/ABL1-like ALL, although demonstrating higher MRD levels at the end of induction, had a survival similar to that of patients with non-BCR/ABL1-like ALL when treated with intensive therapies that included transplantation procedures. In contrast, Heatley et al, 20 who analyzed patients enrolled in the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) ALL8 clinical trial, which was based on MRD evaluation for risk stratification, demonstrated that despite a risk-adjusted treatment approach, a high rate of disease recurrence was recorded among children who were retrospectively identified as having Ph-like ALL.
In adult cohorts, all studies appear to demonstrate a shorter survival for patients with BCR/ABL1-like ALL compared with those with non-BCR/ABL1-like disease and an association with MRD persistence. [8] [9] [10] [11] [12] Further stratification of patients according to age cohorts highlighted that the differences in survival between patients with BCR/ABL1-like and those with non-BCR/ABL1-like disease is evident in young adults (those aged 21-39 years) and adults (those aged 40-59 years), but not in elderly patients (those aged 60-86 years); the latter result most likely is impaired by the low number of elderly patients included in the study and because of the frequent comorbidities that limit compliance to treatment. 8 The issue that remains unsolved is whether intensive treatments are capable of overcoming the negative prognostic impact of the BCR/ABL1-like status. In the study by Jain et al, 10 the outcome of patients with BCR/ABL1-like ALL, which overall was inferior to that of patients with non-BCR/ ABL1-like ALL, did not differ between patients enrolled in the intensive Berlin-Frankfurt-Munster protocol and those treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD). However, this comparison was negatively affected by the low number of patients. In the adult cohort examined by Herold et al, 9 the intensive German 
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Multicenter Study Group for Adult ALL (GMALL 06/99 e 07/03) produced 100% complete remissions, although with a short duration, also in the BCR/ABL1-like subgroup; nonetheless, in the latter subgroup, a lower number of molecular remissions and a higher rate of early relapses were documented. Lastly, the low number of patients with MRD data did not allow us to assess whether the BCR/ABL1-like subtype represents an independent prognostic factor. By studying patients enrolled in different GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) clinical trials, our group 12 demonstrated that patients with BCR/ABL1-like ALL have a lower rate of complete remissions and a worse event-free survival compared with non-BCR/ABL1-like ALL cases. It is important to note that this result recently was confirmed in a cohort of adult patients with B-lineage ALL who were enrolled in the pediatric-inspired MRD-driven protocol GIMEMA LAL1913. 27 Furthermore, within this context, the percentage of MRD-positive patients was significantly higher among those with BCR/ABL1-like ALL compared with those with non-BCR/ABL1-like ALL, indicating that a BCR/ABL1-like signature should be regarded as an independent prognostic marker. 27 Genetic Features: How Many Subsets?
As already mentioned, patients with BCR/ABL1-like ALL display a transcriptional profile that is similar to that of true BCR/ABL1-positive cases and carry a similar incidence of IKZF1 deletions. 6, 7 Concomitantly, alterations in the JAK/STAT pathway have been reported. 13, 14 The advent of next-generation sequencing technologies permitted us to further elucidate the BCR/ABL1-like genetic scenario. Using RNA sequencing, Roberts et al 28 demonstrated that 90% of patients with BCR/ABL1-like ALL are characterized by TK or cytokine receptor mutations/ rearrangements. This landmark publication was followed by large-scale comprehensive studies of pediatric and adult patients with BCR/ABL1-like ALL that allowed on the one hand, to reveal the high degree of heterogeneity of BCR/ABL1-like ALL and, on the other hand, to recognize some common patterns, summarized below.
Cytokine receptor alterations and JAK/STAT pathway mutations CRLF2 is located in the pseudoautosomal region (proteaseactivated receptor 1 [PAR1]) of sex chromosomes at Xp22.3/Yp11.3 and encodes for a member of the type I cytokine receptor family that dimerizes with the interleukin 7 receptor (IL-7-R) to form the heterodimeric thymic stromal lymphopoietin receptor, which has been implicated in early B-cell development.
High CRLF2 expression results from 2 principal mechanisms: a cryptic chromosomal translocation that juxtaposes CRLF2 to the immunoglobulin heavy-chain locus (IGH) 29 or an interstitial deletion of part of the PAR1 region centromeric to CRLF2, resulting in a CRLF2 positioning under the control of the P2Y receptor family member 8 (P2RY8) promoter. 30 More rarely, elevated CRLF2 expression is sustained by the F232C mutation. 10, 31 Initially, CRLF2 overexpression has been associated with JAK1/2 mutations, IKZF1 deletions, and an unfavorable prognosis in pediatric and adult patients with BCR/ABL1-negative ALL. 14, 31, 32 In addition, a strong association between Down syndrome-associated B-lineage ALL, CRLF2 deregulation, and JAK mutations has been reported. [33] [34] [35] Subsequently, CRLF2 overexpression was linked to the BCR/ABL1-like profile; it was detected in approximately 24% of pediatric patients with standardrisk BCR/ABL1-like ALL 16 and in 55% of high-risk pediatric patients. 21 In adolescent and adult patients with BCR/ABL1-like ALL, CRLF2 overexpression is reported to be detected in approximately 50% to 60% of cases. [8] [9] [10] [11] [12] 16 P2RY8/CRLF2 prevails in children, whereas IGH/CRLF2 is more frequent in adolescents and adults, which is in agreement with the increased incidence of other IGH rearrangements reported in the older ALL population. 8, 10, 36, 37 CRLF2 deregulation is not sufficient to cause overt leukemia. 33 As such, approximately 50% of CRLF2-deregulated pediatric cases carry mutations in the JAK/ STAT pathway members. 16, 21 The most common mutations target JAK2, JAK1, IL-7-R, and CRLF2. [8] [9] [10] [11] [12] 16, 24, 38 JAK2 mutations occur mainly in the highly conserved TK or pseudokinase domains, with the substitution of arginine 683, particularly R683G, in the pseudokinase domain of JAK2 being the most frequent. JAK1 mutations are less common and are prevalently represented by V658F, the homolog of JAK2 V617F, which is typical of myeloproliferative neoplasms. IL-7-R mutations target exon 6 and are mainly represented by in-frame insertion/ deletions in the juxtamembrane-transmembrane domain or, less frequently, substitutions that introduce a serine-to-cysteine at amino acid 185 in the extracellular domain. 38 These gain-of-function mutations lead to cytokine-independent growth in lymphoid progenitors.
The abovementioned genetic lesions cooperate with CRLF2 to activate the JAK/STAT cascade and cytokine-independent growth in cytokine-dependent mouse hematopoietic cells. 33 Among patients with BCR/ABL1-like ALL, the survival of those with CRLF2 overexpressed/rearranged Cancer January 15, 2019 is reported to be inferior when compared with non-CRLF2-overexpressing cases. 10, 16 However, in the study of the pediatric cohort analyzed by van der Veer et al, the BCR/ABL1-like signature and IKZF1 deletion but not high expression of CRLF2 were reported to be negative prognostic factors. 39 Another cytokine receptor is the erythropoietin receptor (EpoR). EpoR rearrangements are a rare event, being detected in approximately 3.9% of pediatric patients and 5.2% of adult patients with BCR/ABL1-like ALL. 8, 16, 21 A cryptic insertion of EpoR in the IGH or kappa locus (and less frequently in the THADA and LAIR1 genes) causes the overexpression of a truncated EpoR protein that lacks negative regulatory tyrosine residues and activates the JAK/STAT cascade. 40 In contrast to CRLF2-rearranged cases, JAK1/2 mutations are not detected in this subset, suggesting that EpoR rearrangements are self-sufficient to induce an oncogenic signal transduction, similar to other TK rearrangements.
8,16

TK rearrangements
One of the main features of BCR/ABL1-like ALL is the presence of fusion genes involving a TK belonging to 2 main classes: the ABL class and JAK2 rearrangements.
The ABL class includes rearrangements of ABL1, ABL2, colony-stimulating factor 1 receptor (CSF1R), and platelet-derived growth factor receptor beta (PDGFRB) with multiple partner genes, with ABL1 and PDGFRB being the most frequent target. ABL class rearrangements occur in approximately 11% to 14% of pediatric patients with ALL 16, 21, 26, 41 and in approximately 10% of adolescents and adults, whereas their incidence decreases in older adults, representing only 2.8% of the molecular lesions. 8, 16 The constitutively active TK is a suitable target for TK inhibitors (TKIs), thus making the recognition of ABL class lesions of pivotal therapeutic relevance.
JAK2 rearrangements are detected in approximately 7% to 8% of cases. 8, 16, 21 The fusion is composed by the carboxyl terminal portion of JAK2, including the kinase domain. JAK2 is the most promiscuous 5' kinase gene with the highest number of partners. Among them, it is worth mentioning EBF1, ETV6, PAX5, and BCR, known to have a role in ALL. These rearrangements generate the constitutive activation of JAK2, thus supporting the use of JAK inhibitors. These data indicate that the BCR/ABL1-like ALL profile is sustained by at least 2 mechanisms, either a TK-activating fusion or CRLF2 overexpression with a concomitant JAK/STAT mutation. Thus, it is tempting to speculate that we are dealing with 2 diseases.
In addition to these major subgroups, a minority of cases harbor other kinase rearrangements (NTRK3, PTK2B, and BLNK ), other kinase lesions (FLT3, TYK2, and SH2B adapter protein 3 [SH2B3] mutations), or RAS pathway mutations. 16 From a prognostic point of view, patients with JAK2-rearrangements together with those with CRLF2-rearrangements experience the poorest outcomes compared with the other molecular subtypes. 10, 16 It is worth mentioning that to our knowledge all the studies to date have documented that a variable percentage of cases lack kinase-activating lesions, thus causing uncertainty on the fact that these cases are "true" BCR/ ABL1-like ALL; it is interesting to note that the patients without kinase rearrangements indeed have a better prognosis compared with patients harboring these rearrangements, thus again reinforcing the suspicion regarding their correct classification. 42, 43 The various mechanisms underlying the BCR/ ABL1-like ALL signatures and their distribution in different age cohorts are shown in Figures 3 and 4 . 44 
Copy number aberrations in patients with BCR/ ABL1-like ALL
In addition to mutations and fusion genes, alterations in the copy number of genes involved in B-cell development have been reported and may represent cooperating events. The most frequent copy number aberration in BCR/ABL1-like ALL is IKZF1 deletion, which is documented in approximately 27% of pediatric cases and in approximately 70% of high-risk pediatric patients with ALL.
16 IKZF1 deletions initially were recognized as a negative prognostic marker both in patients with BCR/ ABL1-positive and those with BCR/ABL1-negative ALL. 7, [45] [46] [47] [48] [49] In adult patients with BCR/ABL1-like ALL, IKZF1 deletion occurs in approximately 70% to 80% of patients. [8] [9] [10] [11] [12] IKZF1 deletions are significantly more common in patients carrying a CRLF2 rearrangement compared with patients with CRLF2 deregulation. 8, 16 Moreover, Boer et al 41 found that deletions, other than 4-7 or full deletions, occurred more frequently in the TK fusion-positive cases compared with the TK fusionnegative cases (43% vs 15%).
Other frequently deleted genes in BCR/ABL1-like ALL are EBF1 and BTG1 (20%-40% and approximately 30% of cases, respectively), which indeed are reported to be associated with a worse outcome. [8] [9] [10] 12, 48 EBF1 deletions are enriched in cases carrying the EBF1-PDGFRB fusion due to an interstitial 5q deletion.
Cancer January 15, 2019 Furthermore, cyclin-dependent kinase inhibitor 2A (CDKN2A)/2B deletions are detected in approximately 50% of patients with BCR/ABL1-like ALL. However, to the best of our knowledge, there is no consensus regarding the association with a specific BCR/ABL1-like subset; indeed, among adult patients with B-lineage ALL, Roberts et al 8 reported an enrichment of CDKN2A/2B deletions in those cases harboring rearrangements, whereas Boer et al 41 reported that CDKN2A/2B deletions were significantly more frequent in patients with TK fusion-negative disease.
Therapeutic Implications
The poor outcome of patients with BCR/ABL1-like ALL and the identification of actionable lesions has opened the way to the treatment of patients with genetic-driven approaches because the majority of lesions converge on a limited number of pathways. Indeed, it is possible to block the aberrant fusion protein as ABL class lesions or JAK alterations, or to interfere with the aberrantly activated downstream pathways because cytokine receptor and JAK alterations result in the phosphorylation of molecules of the JAK/STAT, phosphatidylinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), and/ or MEK/ERK pathways (Fig. 4) . 44 Patients with BCR/ABL1-like ALL who carry ABL class alterations, although a minority, were the first to be treated with successful results, given the solid experience of treating patients with BCR/ABL1-positive ALL with TKIs of first, second, and third generations. In vitro and ex vivo experiments allowed to demonstrate that imatinib and dasatinib were able to inhibit STAT5 (a downstream player of the signaling cascade) phosphorylation and proliferation, and to decrease the tumor burden in xenograft models from patients harboring ABL1, ABL2, PDGFRB, and CSF1R fusions. These promising data were confirmed by multiple case studies. In particular, imatinib was able to induce a complete remission in patients harboring EBF1/PDGFRB fusions. 50, 51 Similarly, imatinib, dasatinib, and ponatinib were able to induce a response in 2 adolescent patients and 1 elderly patient harboring RCSD domain containing 1 (RCSD1)/ ABL1. [52] [53] [54] It is interesting to note that the choice of Collette et al 52 was guided by the ex vivo drug response profiling that demonstrated the superiority of ponatinib versus dasatinib. Similarly, our group documented the in vitro efficacy of ponatinib on primary leukemic cells from patients with BCR/ABL1-like ALL, regardless of the underlying lesion. JAK inhibitors have been tested in preclinical models of BCR/ABL1-like ALL harboring CRLF2 rearrangements and/or JAK/STAT pathway lesions. Ruxolitinib, a type I JAK1/2 inhibitor that has been used successfully to treat patients with myelofibrosis, was able to inhibit STAT5 phosphorylation in cells expressing JAK2 rearrangements and was effective in reducing the leukemia burden in JAK2-mutated/CRLF2-rearranged xenografts. 55 Given the constitutive activation of PI3K/Akt/ mTOR in patients with BCR/ABL1-like ALL, alternative approaches have been tested. The mTOR inhibitor rapamycin was able to induce a profound response in patient-derived xenografts (PDX) carrying different JAK-activating lesions (i.e., JAK2-mutated/CRLF2-rearranged, CRFL2-rearranged, JAK2-rearranged, JAK1-mutated, IL-7-R-mutated lesions). 55 The same authors subsequently demonstrated the efficacy of the dual PI3K/mTOR inhibitor gedatolisib in inhibiting cell proliferation and the superiority of combination approaches; in fact, the coadministration of gedatolisib and ruxolitinib proved more effective in JAK2-mutated/CRLF2-rearranged patient-derived xenograft models compared with single-agent therapies. Similarly, gedatolisib and dasatinib treatment demonstrated an augmented therapeutic efficacy in ABL/PDGFRB models compared with monotherapy. 44 These data suggest that dual pathway-targeting approaches may have higher antileukemic potential and might overcome compensatory signaling mechanisms. Consistent results were obtained by Zhang et al, 56 who tested the activity of ruxolitinib and BBT594, a type II JAK inhibitor, alone or in combination with rapamycin or AZD2014, a second-generation mTOR inhibitor. Lastly, an elegant study by Roberts et al 57 recently demonstrated that single-agent treatment with dasatinib in patient-derived xenograft models of BCR/ABL1-like ALL harboring ABL class lesions has a cytostatic effect, whereas the addition of dexamethasone was able to reduce the leukemic burden to undetectable levels. Likewise, the efficacy of ruxolitinib was found to be highly enhanced by the addition of dexamethasone in patient-derived xenograft models harboring JAK2 rearrangements. These findings provide the rationale for testing TKIs and JAK inhibitors added to a chemotherapy backbone.
Several limitations to the use of JAK inhibitors alone have emerged. Steeghs et al 58 recently demonstrated that the JAK inhibitors momelotinib and ruxolitinib indeed are effective in reducing the viability of JAK2-rearranged cells, whereas their efficacy in JAK2-mutated cells is highly dependent on the activation status of CRLF2 by heterodimeric thymic stromal lymphopoietin. In addition, a reactivation of JAK2 has been observed that could be overcome by using type II inhibitors. These encouraging studies provided the rationale for testing these drugs as single agents or in combination in clinical trials, as described below.
Treatment of BCR/ABL1-Like ALL
As mentioned, it is not clear whether individuals with BCR/ABL1-like ALL (if adequately identified, which still remains a challenge) should be treated differently upfront or, instead, if a treatment switch (or intensification with allogeneic stem cell transplantation and targeted approaches) should be limited to those patients who are positive for MRD. In addition, although there is a general consensus that patients should receive a TKI, to the best of our knowledge the best TKI has not been defined to date because of the plethora of genetic lesions. Two alternative approaches have been proposed. The first is based on the underlying lesion, considering dasatinib for patients with ABL class genes and JAK2 inhibitors, particularly ruxolitinib, for those with JAK/STAT pathway lesions. However, this approach is not applicable to all hematologic centers; furthermore, the preliminary results from The University of Texas MD Anderson Cancer Center in Houston regarding 9 patients with recurrent/refractory BCR/ABL1-like ALL have not shown significant responses. 22 Another approach could be the use of ponatinib, as suggested by our group and tested in a patient by Collette et al. 12, 52 Third, the role of immunotherapy, namely blinatumomab and inotuzumab as well as chimeric antigen receptor (CAR) T cells, remains to be determined conclusively. • -NCT02003222: a randomized phase III study that compares chemotherapy combined with blinatumomab with chemotherapy as single treatment in the induction phase of adult and elderly patients with BCR/ ABL1-negative B-lineage ALL; in this framework, one of the objectives is to assess the role of MRD in patients with BCR/ABL1-like ALL and the efficacy of blinatumomab in patients with and without BCR/ ABL1-like ALL.
• -NCT03367299: a phase II trial for adult BCR/ABL1-negative B-lineage ALL, based on the same backbone as the GIMEMA LAL1913 protocol, and implemented with the addition of 2 cycles of blinatumomab. All patients enrolled in this trial will be evaluated for the BCR/ABL1-like predictor 12 ; as a consequence, the role of blinatumomab in the management of patients with BCR/ABL1-like ALL will be addressed.
Both the NCT02003222 and NCT03367299 trials will be pivotal to determining whether blinatumomab can overcome the negative prognostic impact of the BCR/ ABL1-like profile.
Conclusions
The identification of BCR/ABL1-like ALL can be regarded as a success of the application of "omics" technologies because these patients, characterized by an Cancer January 15, 2019 unfavorable outcome, previously were not recognized. Given their poor prognosis and the persistence of high MRD levels at the time of induction/early consolidation, the recognition of this subset of patients with B-lineage ALL at the time of diagnosis should be pursued as much as possible to design ad hoc upfront treatments, possibly combining chemotherapy with targeted approaches and close MRD monitoring. This progress is likely to increase to up to approximately 50% the number of adult patients with B-lineage ALL who can benefit from targeted treatments, including both those with BCR/ABL1-positive and BCR/ABL1-like ALL. Finally, the use of immunotherapy, represented by blinatumomab, inotuzumab, and CAR-T cells, represents an attractive alternative approach because they are based on an antigen-directed therapy (CD22 for inotuzumab, CD19 for blinatumomab, and both CD22 and CD19 for CAR-T cells) and on immune system stimulation (blinatumomab and CAR-T products), and therefore are not dependent on a specific molecular target. As mentioned, the role of blinatumomab currently is being explored in the frontline setting, whereas the role of inotuzumab and CAR-T cells most likely will be ruled out upon retrospective evaluation of BCR/ABL1-like cases. 
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